Cataract/anterior segment

Patients with active thyroid eye disease who were treated with teprotumumab had significant improvements in proptosis, diplopia, and quality of life compared to placebo, according to an article published in the New England Journal of Medicine. Teprotumumab, which received FDA approval on January 21, 2020, is the first approved treatment for adults with thyroid eye disease.

In the phase 3 OPTIC clinical trial evaluating the insulin-like growth factor I receptor (IGF-IR) teprotumumab-trbw for thyroid eye disease, patients were assigned…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Oct 18, 2019

AAO 2019: Phacoemulsification With Excisional Goniotomy Reduces IOP

Phacoemulsification with excisional goniotomy using the Kahook Dual Blade (New World Medical, Rancho Cucamonga, CA) reduces intraocular pressure (IOP), according to a recent analysis presented at the 2019 American Academy of Ophthalmology meeting. It is the longest follow-up study of…

Journal Scan

  1. Jan 24, 2020

Data From Phase 3 Clinical Trial of Teprotumumab Demonstrates Improvements in Proptosis, Quality of Life

Patients with active thyroid eye disease who were treated with teprotumumab had significant improvements in proptosis, diplopia, and quality of life compared to placebo, according to an article published in the New England Journal of Medicine. Teprotumumab, which received…